Brief: Antengene And UCB Enter Global License Agreement For ATG-201, A CD19/CD3 Bispecific T-Cell Engager For Autoimmune Diseases
03/03/2026 22:03
March 3 (Reuters) - Antengene Corp Ltd 6996.HK: ANTENGENE AND UCB ENTER GLOBAL LICENSE AGREEMENT FOR ATG-201, A CD19/CD3 BISPECIFIC T-CELL ENGAGER FOR AUTOIMMUNE DISEASES ANTENGENE CORP - TO RECEIVE $80 MILLION UPFRONT, ELIGIBLE FOR OVER $1.1 BILLION IN MILESTONES AND ROYALTIES Source text: ID:nPrev8Ww3a Further company coverage: 6996.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106